Losmapimod
Phase 2Terminated 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Facioscapulohumeral Muscular Dystrophy (FSHD)
Conditions
Facioscapulohumeral Muscular Dystrophy (FSHD)
Trial Timeline
Feb 13, 2020 → Nov 7, 2024
NCT ID
NCT04264442About Losmapimod
Losmapimod is a phase 2 stage product being developed by Fulcrum Therapeutics for Facioscapulohumeral Muscular Dystrophy (FSHD). The current trial status is terminated. This product is registered under clinical trial identifier NCT04264442. Target conditions include Facioscapulohumeral Muscular Dystrophy (FSHD).
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04264442 | Phase 2 | Terminated |
| NCT04004000 | Phase 2 | Terminated |
Competing Products
12 competing products in Facioscapulohumeral Muscular Dystrophy (FSHD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ACE-083 + ACE-083 or placebo | Merck | Phase 2 | 52 |
| ACE-083 | Merck | Phase 2 | 52 |
| Placebo + RO7204239 | Roche | Phase 2 | 52 |
| AOC-1020 + Placebo | Avidity Biosciences | Phase 3 | 74 |
| Apitegromab + Placebo | Scholar Rock Holding | Phase 2 | 49 |
| Losmapimod oral tablet + Placebo oral tablet | Fulcrum Therapeutics | Phase 2 | 44 |
| Losmapimod + Placebo oral tablet | Fulcrum Therapeutics | Phase 3 | 69 |
| Losmapimod | Fulcrum Therapeutics | Phase 2 | 44 |
| ATYR1940 | aTyr Pharma | Phase 1/2 | 33 |
| ATYR1940 | aTyr Pharma | Phase 1/2 | 33 |
| Placebo + ATYR1940 | aTyr Pharma | Phase 1/2 | 33 |
| ATYR1940 | aTyr Pharma | Phase 1/2 | 33 |